ArticleCardiovascular research2013
Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension.
Article in Cardiovascular research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
179 citing papers in PubMed, 3 syntheses or guidelines pooled it, 301 citations in OpenAlex.
- Meta-analysis of the association between interleukin-17 and ischemic cardiovascular disease.BMC cardiovascular disorders · 2024Pooled it
- Pooled it
- Patho-immune Mechanisms of Hypertension in HIV: a Systematic and Thematic Review.Current hypertension reports · 2019Pooled it
- Sex-dependent modulation of T and NK cells and gut microbiome by low sodium diet in patients with primary aldosteronism.Frontiers in immunology · 2024Trial
- Selected Vascular, Inflammatory, and Lipid Parameters in Patients with Selected Keratinization Disorders: Preliminary Data from a Retrospective Observational Study.Journal of clinical medicine · 2026Article
- Myeloid transglutaminase 2 regulates Treg-Th17 balance in a female model of angiotensin II-induced hypertension and vascular stiffening.American journal of physiology. Heart and circulatory physiology · 2026Article
- Spironolactone ameliorates the endothelial dysfunction induced by visceral adipose tissue in obese female mice exposed to early life stress.Journal of applied physiology (Bethesda, Md. : 1985) · 2026Article
- Effects and mechanisms of probiotics supplement on hypertension.Journal of hypertension · 2026Review
- Aberrant Uteroplacental and Vascular Signaling and Remodeling by Matrix Metalloproteinases in Pregnancy-Related Hypertension and Preeclampsia.Biomolecules · 2026Review
- Antagonizing IL-17A Reduces Vascular Inflammation and Attenuates Oxidative Stress Formation but Does Not Significantly Improve Vascular Dysfunction Induced by One Week of Angiotensin II Treatment.Antioxidants (Basel, Switzerland) · 2026Article
- Whole blood TNF-α expression and apoptotic endothelial microparticles reveal early vascular injury in pediatric obesity.International journal of obesity (2005) · 2026Article
- Potential role of the spleen in the development of arterial hypertension in humans.Journal of hypertension · 2026Article
- Potential association between IL-17A inhibition and blood pressure reduction in patients with axial spondyloarthritis.Frontiers in immunology · 2026Article
- Ultrasound Renal Stress Test Assessment in Moderate-to-Severe Psoriasis: A Pilot Study.Psoriasis (Auckland, N.Z.) · 2026Article
- Adaptive Immune System in Hypertension: Implicating the Role of T Cells.Current cardiology reviews · 2025Article
- Hypertension promotes bone loss and fragility by favoring bone resorption in mouse models.The Journal of clinical investigation · 2025Article
- Immunology of Hypertension: Pathophysiological and Therapeutic Aspects.International journal of molecular sciences · 2025Review
- Psychological trauma increases blood pressure sensitivity to angiotensin II via T-lymphocytes independent of psychopathology.bioRxiv : the preprint server for biology · 2025Article
- Uncovering immune pathways for therapeutic targeting of hypertension.Expert opinion on therapeutic targets · 2025Review
- Identification of potential biomarkers for hypertension based on transcriptomic analysis in rats.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
119 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
aimsElevated levels of pro-inflammatory cytokine interleukin-17A (IL-17) are associated with hypertensive autoimmune diseases; however, the connection between IL-17 and hypertension is unknown. We hypothesized that IL-17 increases blood pressure by decreasing endothelial nitric oxide production. METHODS AND
resultsAcute treatment of endothelial cells with IL-17 caused a significant increase in phosphorylation of the inhibitory endothelial nitric oxide (NO) synthase residue threonine 495 (eNOS Thr495). Of the kinases known to phosphorylate eNOS Thr495, only inhibition of Rho-kinase prevented the IL-17-induced increase. IL-17 caused a threefold increase in the Rho-kinase activator RhoA, and this was prevented by an IL-17 neutralizing antibody. In isolated mouse aortas, IL-17 significantly increased eNOS Thr495 phosphorylation, induced RhoA expression, and decreased NO-dependent relaxation responses, all of which were prevented by either an IL-17 neutralizing antibody or inhibition of Rho-kinase. In mice, IL-17 treatment for 1 week significantly increased systolic blood pressure and this was associated with decreased aortic NO-dependent relaxation responses, increased eNOS Thr495 phosphorylation, and increased RhoA expression. Inhibition of Rho-kinase prevented the hypertension caused by IL-17.
conclusionThese data demonstrate that IL-17 activates RhoA/Rho-kinase leading to endothelial dysfunction and hypertension. Inhibitors of IL-17 or Rho-kinase may prove useful as anti-hypertensive drugs in IL-17-associated autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.